Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Liminal Biosciences engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: small molecule therapeutics and plasma-derived therapeutics. The small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
Laval, QC, H7V 4B4, Canada